Carbamazepine
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
Carbamazepine: From Established Antiseizure Use to Trigeminal Nerve Neoplasm
One-Sentence Summary
Carbamazepine is a sodium channel–blocking antiseizure medicine that is also used for trigeminal neuralgia. The TxGNN model predicts it may be useful for trigeminal nerve neoplasm. This is supported by 1 registered clinical trial (which does not test carbamazepine) and 20 publications (which show symptomatic pain relief, not any anti-tumour effect), so the prediction most likely reflects the existing trigeminal neuralgia link.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the SAHPRA registration records supplied. Carbamazepine is generally known as an antiseizure and neuralgia medicine. |
| Predicted New Indication | Trigeminal nerve neoplasm |
| TxGNN Prediction Score | 99.998% (model rank 52) |
| Evidence Level | L4 |
| South Africa Market Status | Marketed |
| Number of SAHPRA Registrations | 2 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in this Evidence Pack. Carbamazepine is known to be a voltage-gated sodium channel blocker. This reduces abnormal, repetitive nerve firing, which is why it is used for trigeminal neuralgia.
Tumours of, or near, the trigeminal nerve (for example schwannoma, meningioma or lymphoma) often present with facial pain that looks like trigeminal neuralgia. The literature shows carbamazepine being prescribed in these patients for pain control. That is probably why the model links the drug to this disease.
The link is symptomatic, not disease-modifying. Nothing in the evidence shows carbamazepine shrinking or treating a tumour. The prediction therefore appears to be a re-labelling of an existing use (neuralgic pain) rather than a true new therapeutic indication.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT06853119 | N/A | Not yet recruiting | 120 | MRI study of brain network and structural changes in trigeminal neuralgia. It does not study a neoplasm and does not test carbamazepine. |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 36824641 | 2022 | Review | Acta Clin Croat | Treatment options for trigeminal neuralgia. Notes that the cause can be vascular compression or a tumour process. |
| 17997704 | 2007 | Review | Expert Rev Neurother | Overview of medical and surgical treatments for trigeminal neuralgia. |
| 30741017 | 2023 | Case report | Br J Neurosurg | Primary lymphoma of the trigeminal nerve with facial pain. Carbamazepine did not improve symptoms. |
| 25142539 | 2014 | Case report | Rinsho Shinkeigaku | Lymphoma spreading along the trigeminal nerve, first diagnosed as classical neuralgia. Pain improved on carbamazepine, then stopped responding as other cranial nerve signs appeared. |
| 15235745 | 2004 | Case report | Arq Neuropsiquiatr | Primary melanoma of Meckel’s cave. Pain was not relieved by carbamazepine. |
| 25433061 | 2014 | Case report | No Shinkei Geka | Cerebellopontine angle lipoma with neuralgia. Carbamazepine control was inadequate because of side effects. |
| 9109911 | 1997 | Case report | Neurology | Post-irradiation neuromyotonia in facial and trigeminal distribution that responded to carbamazepine. |
| 3181365 | 1988 | Preclinical (rat) | Exp Neurol | Carbamazepine inhibited spontaneous activity in experimental neuromas. This is a nerve-firing effect, not an anti-tumour effect. |
| 33989821 | 2021 | Case report | World Neurosurg | Petroclival meningioma causing trigeminal neuralgia, treated surgically. |
| 32454201 | 2020 | Case report | World Neurosurg | Endoscopic resection of a pterygopalatine fossa trigeminal schwannoma. |
No randomised trials were found.
South Africa Market Information
| Registration Number | Product Name | Dosage Form |
|---|---|---|
| Reg. No. 29/2.5/0195 | Zecarb | Tablet |
| Reg. No. D/2.5/204 | Tegretol s | Suspension |
The registration records supplied do not include approved indication text.
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
Conclusion and Next Steps
Decision: Hold
Rationale: The only registered trial does not test carbamazepine or a neoplasm. The literature shows symptomatic pain relief in some tumour-related neuralgia and no anti-tumour activity. The case reports also show that carbamazepine can give temporary pain relief while the underlying tumour progresses, so its use does not address the neoplasm.
Ranks 2–8 of the model’s predictions are mostly reflex seizure types. These are mechanistically plausible but rest only on case-level evidence, so they are research questions rather than actionable indications.
To proceed, the following is needed:
- The SAHPRA Professional Information (warnings, contraindications and approved indications) for Zecarb and Tegretol suspension.
- Detailed mechanism of action data from DrugBank.
- Any evidence of a direct anti-tumour effect of carbamazepine in nerve-sheath or skull-base tumours. Absent that, the prediction should be regarded as pain control in tumour-associated neuralgia, not treatment of the neoplasm.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.